Esperion Therapeutis.Inc. buy Global_Player
Summary
This prediction ended on 27.04.24 with a price of €1.83. With a performance of -1.11%, the BUY prediction by Global_Player finished with a loss. Global_Player has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | -11.202% | -11.202% | 26.509% |
| iShares Core DAX® | 1.644% | 4.865% | 25.089% |
| iShares Nasdaq 100 | 0.747% | 2.923% | 8.975% |
| iShares Nikkei 225® | 2.442% | 6.212% | 21.408% |
| iShares S&P 500 | 0.618% | 2.843% | 5.726% |
According to Global_Player what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Cons
Comments by Global_Player for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Global_Player for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
29.08.25
29.08.26
15.09.25
Esperion Therapeutis.Inc.
26.02.25
26.02.26
01.03.25
Esperion Therapeutis.Inc.
28.08.23
28.08.24
30.08.23
Esperion Therapeutis.Inc.
07.12.22
07.12.23
11.12.22
Esperion Therapeutis.Inc.
26.07.21
26.07.22
08.08.21


